Catalent Valuation
Is CTLT * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CTLT * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CTLT * (MX$1020) is trading above our estimate of fair value (MX$164.81)
Significantly Below Fair Value: CTLT * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CTLT *?
Key metric: As CTLT * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is CTLT *'s PS Ratio? | |
|---|---|
| PS Ratio | 2.5x |
| Sales | US$4.38b |
| Market Cap | US$10.92b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.6x |
| Enterprise Value/EBITDA | 31.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does CTLT *'s PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.6x | ||
LAB B Genomma Lab Internacional. de | 1.4x | 9.9% | Mex$24.7b |
MANKIND Mankind Pharma | 9.3x | 18.4% | ₹1.0t |
4523 Eisai | 1.7x | 5.6% | JP¥1.3t |
600196 Shanghai Fosun Pharmaceutical (Group) | 1.7x | 7.9% | CN¥65.1b |
CTLT * Catalent | 2.5x | 6.8% | Mex$10.9b |
Price-To-Sales vs Peers: CTLT * is good value based on its Price-To-Sales Ratio (2.5x) compared to the peer average (6.7x).
Price to Sales Ratio vs Industry
How does CTLT *'s PS Ratio compare vs other companies in the Global Pharmaceuticals Industry?
| 189 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 189 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: CTLT * is good value based on its Price-To-Sales Ratio (2.5x) compared to the Global Pharmaceuticals industry average (2.7x).
Price to Sales Ratio vs Fair Ratio
What is CTLT *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.5x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate CTLT *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
ICON
US$16.8b
A clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.
ICLR N
US$4,286.08
7D
0%
1Y
-7.7%
Laboratorios Farmaceuticos Rovi
€3.2b
Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.
ROVI N
€1,416.38
7D
0%
1Y
54.7%
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%